(NASDAQ: GRTS) Gritstone Bio's forecast annual revenue growth rate of 73.24% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Gritstone Bio's revenue in 2024 is $16,344,000.On average, 3 Wall Street analysts forecast GRTS's revenue for 2024 to be $6,311,501,630, with the lowest GRTS revenue forecast at $1,498,442,276, and the highest GRTS revenue forecast at $11,669,805,686. On average, 3 Wall Street analysts forecast GRTS's revenue for 2025 to be $10,347,881,479, with the lowest GRTS revenue forecast at $692,343,094, and the highest GRTS revenue forecast at $21,770,561,868.
In 2026, GRTS is forecast to generate $6,518,910,361 in revenue, with the lowest revenue forecast at $779,621,472 and the highest revenue forecast at $12,258,199,250.